Remdesivir Shows Positive Proof of Concept in NIAID Trial of Hospitalized COVID-19 Patients

30 avril 2020

Source : Clinical OMICS



In the first clinical study in the U.S. of a therapeutic targeting SARS-CoV-2, the National Institute of Allergy and Infectious Disease (NIAID) of the NIH released preliminary data yesterday showing that Gilead Sciences’ drug candidate remdesivir outperformed placebo in treating COVID-19 in hospitalized patients.


Lire la suite de l’article ICI.

© Les Hôpitaux Universitaires de Strasbourg 2020 - Tous droits réservés